吉非贝齐与非诺贝特降脂疗效比较

Gemfibrozil vs fenofibrate in treating hyperlipidemia

高脂血症２１０例，其中１０９例（男性６０例，女性４９例；年龄５８±ｓ８ａ）采用吉非贝齐６００ｍｇ，ｐｏ，ｂｉｄ共治疗１２ｗｋ；另１组１０１例（男性６６例，女性３５例；年龄５９±８ａ）采用非诺贝特１００ｍｇ．ｐｏ，ｔｉｄ共１２ｗｋ。结果：降三酰甘油，降总胆固醇及升高高密度脂蛋白胆固醇，吉非贝齐组依次为５３．０％，１９．４％及２６．８％，（Ｐ值均为＜０．０１），非诺贝特依次为４１．０％，２２．０％及２２．０％（Ｐ值均＜０．０１），２组组间比较无差异（Ｐ＞０．０５）；前者有４例，后者有５例一过性ＧＰＴ（ＡＬＴ）升高。

In 210 patients with hyperlipemia,109 patients(M60,F49;age 58±s 8 a) were treated with gemfibrozil 600 mg,po,bid×12 wk,and 101 patients(M66,F35;age 59±8a) were treated with fenofibrate 100 mg,po,bid×12 wk.Results shwed that in gemfibrozil group the levels of triglyceride(TG) and total cholesterol(TC) decreased 53.0%and 19.4% respectively, and high density lipoprotein cholesterol(HDL-ch) increased 26.8%(all P<0.01).In fenofibrate group,the levels of TG and TC decreased 41.0% and 22.0%respectively and HDL-ch increased 22.0% (all P<0.01).But the difference between the two groups was non significant (P>0.05).No serious side effects were found during the therapeutic period,but 4 patients in gemfibrozil group and 5 patients in fenofibrate group had transient increase of GPT activity.